A pilot test has been conducted and production platform established in the GMTCM Park, covering an area of 7,214 m2 with a building area of 17,782.8 m2. The Guangdong–Macao Pharmaceuticals Co., Ltd is the main operating entity that linked to the Guangdong–Macao Traditional Chinese Medicine Technology Industrial Park Development Co., Ltd. This platform is designed in accordance with the advanced medicine production quality management regulations of the European Union and the USA. At the first phase of the platform, the Traditional Chinese Medicine treatment prior to extraction and extraction workshop, oral solid dosage workshop and liniment workshop, will be constructed and concluded in 2017, including five production lines for tablet, capsule, pill, granule and liniment. The production lines concluded can accommodate the clients’ needs of passing the GMP authentication of medicine of the European Union or the USA. At the same time, the pilot test and production platform aligns with the other high-standard research and development platform and Incubation Center of the GMTCM Park. These form an integrated system that offers the professional services oriented by the spirit of craftsmanship.

The manpower, equipment and facilities, materials, production process, packaging and transportation, quality control, and so on that are responsible for conducting pilot tests and production platform are strictly in compliance with the relevant national regulations and standards.

The pilot test and production platform aim at providing the internal and external users of the GMTCM Park with clinical testing samples, registration samples and commissioned professional manufacturing services. The platform offers technical support to the users of the GMTCM Park that makes the existing quality defects visible, improves the product quality, decreases the pressure of finance for the enterprises and fosters faster growth.